img Leseprobe Leseprobe

Pharmaceutical Regulatory Environment

Challenges and Opportunities in the Gulf Region

Stuart Walker, Sam Salek, Mohammed Al-Rubaie, ...

PDF
ca. 53,49
Amazon iTunes Thalia.de Weltbild.de Hugendubel Bücher.de ebook.de kobo Osiander Google Books Barnes&Noble bol.com Legimi yourbook.shop Kulturkaufhaus ebooks-center.de
* Affiliatelinks/Werbelinks
Hinweis: Affiliatelinks/Werbelinks
Links auf reinlesen.de sind sogenannte Affiliate-Links. Wenn du auf so einen Affiliate-Link klickst und über diesen Link einkaufst, bekommt reinlesen.de von dem betreffenden Online-Shop oder Anbieter eine Provision. Für dich verändert sich der Preis nicht.

Springer International Publishing img Link Publisher

Naturwissenschaften, Medizin, Informatik, Technik / Allgemeines

Beschreibung

This book compares national and centralised procedure practices and key performance metrics, including current approval times, review practices and pharmacovigilance standards, in the seven Gulf States. Opportunities for an improved regulatory system are identified, which, if fully implemented, could have a significant impact on patients’ access to new medicines.

The Persian Gulf represents the next growth market for the global biopharmaceutical industry but to date there has been limited information about the regulatory review processes employed in these countries. A thorough examination of the strategies currently being implemented by the Gulf States is considered critical to the future regulatory environment in this region.

Pharmaceutical Regulatory Environment: Challenges & Opportunities in the Gulf Region is a must read for those interested in pharmaceutical regulation in the Gulf region.


Weitere Titel in dieser Kategorie
Cover Digital Health
Nilmini Wickramasinghe
Cover Digital Health
Nilmini Wickramasinghe
Cover Dignity of Labour?
Ann Cartwright
Cover Dignity of Labour?
Ann Cartwright

Kundenbewertungen

Schlagwörter

Harmonized centralized review procedure, Seven Gulf Cooperation Council states, pharmacotherapy, National metrics, Regulatory review practices, Market approval for new drugs